Literature DB >> 21133004

The use of dermal autograft for fascial repair of TRAM flap donor sites.

Ali Arab Kheradmand1, Neda Ranjbar Novin, Ramesh Omranipour.   

Abstract

Closure of fascia after transverse rectus abdominis myocutaneous (TRAM) flap has usually been performed with direct closure or synthetic material. The dermal autograft removed from zone IV of the flap is an alternative to reinforce fascial closure. Record of the patients who had been undergone breast and head and neck reconstruction by TRAM flap between 1998-2008 were retrieved. In 34 cases dermal autograft and in 42 cases a synthetic mesh was used for closure of the abdominal fascial defect. All patients were followed by physical examinations for a mean period of 24 months. There were one (2.9%) bulging of the anterior abdominal wall and one (2.9%) wound infection in dermal autograft group and one (2.3%) true hernia in mesh repair group. Dermal autograft is a useful alternative to mesh repair of fascial defects after TRAM flap harvest.

Entities:  

Mesh:

Year:  2010        PMID: 21133004

Source DB:  PubMed          Journal:  Acta Med Iran        ISSN: 0044-6025


  4 in total

1.  Infection of PTFE mesh 15 years following pedicled TRAM flap breast reconstruction: mechanism and aetiology.

Authors:  A Elfaki; A Gkorila; M Khatib; C M Malata
Journal:  Ann R Coll Surg Engl       Date:  2017-10-19       Impact factor: 1.891

2.  Does the use of an acellular dermal graft in abdominal closure after rectus flap harvest impact the occurrence of post-operative hernia?

Authors:  Masoud Saman; Sameep Kadakia; Yadranko Ducic
Journal:  Oral Maxillofac Surg       Date:  2015-04-26

3.  Obesity Should Not Prevent from TRAM Flap Breast Reconstruction in Developing Countries.

Authors:  Sadaf Alipour; Ramesh Omranipour; Rahim Akrami
Journal:  Indian J Surg       Date:  2013-01-31       Impact factor: 0.656

4.  Prevention of Abdominal Bulging Using Onlay Dermal Autografts from Discarded Zone IV TRAM Flap Tissue.

Authors:  Won Seob Lee; Seong Oh Park; Il-Kug Kim
Journal:  J Clin Med       Date:  2022-03-30       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.